Track topics on Twitter Track topics that are important to you
The liquid biopsy company, Lexent Bio, is currently developing a test that will measure a cancer's response to treatment. They hope that the test, Confera, will be made available next year as a laboratory developed test (LDT) with a distributable in vitro diagnostic (IVD) kit to follow. Lexent recently announced a nonexclusive partnership with Illumina to develop the kits.
The post Measuring Cancer’s Response to Treatment with a Liquid Biopsy Kit appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Measuring Cancer’s Response to Treatment with a Liquid Biopsy KitNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...